Phase 3 Stroke Trial, Recruiting NCT06764797 Sponsor: King Saud University Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT06764797
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are at least 18 years old.
  • People who have had a stroke affecting one side of the brain (either a blocked or bleeding stroke) that occurred more than three months ago.
  • People with enough thinking and understanding ability to follow instructions, as measured by a standard memory and thinking test (a score above 24 on the Arabic version of a common cognitive screening test).
  • People with mild-to-moderate muscle stiffness in the affected arm, based on a standardised scale (Modified Ashworth Scale score below 3).
  • People with moderate-to-severe arm movement difficulties after their stroke, as measured by a standard arm function assessment (Fugl-Meyer Assessment score between 10 and 58).

Who may not be able to join:

  • People who have significant vision problems, blind spots in their vision, or difficulty paying attention to one side of their surroundings.
  • People who have a type of language difficulty (aphasia) that makes it hard to understand instructions.
  • People who have a medical reason that would make a type of non-invasive brain stimulation treatment unsafe for them (confirm with trial site).
  • People who have other neurological (brain or nervous system) conditions, or who are currently taking part in another research study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Alaa M. Albishi, Doctor of Philosophy, King Saud University

Phone: +966555090015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
King Saud University
Registry
ClinicalTrials.gov
Start date
19 September 2023
Est. completion
31 May 2025

Where this trial is recruiting

🇸🇦 Saudi Arabia

Primary endpoints

Fugl-Mayer Upper limb assessment (FMA); Wolf motor function test (WMT); box and blocks test (BBT); Nine-Hole Peg Test (NHPT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov